Chains a somatic (tumor-normal) SNV/indel and structural-variant pipeline end to end with GATK Mutect2 (or Strelka2), wiring the somatic-specific machinery - panel-of-normals and gnomAD germline-resource priors, GetPileupSummaries/CalculateContamination, and LearnReadOrientationModel FFPE/oxoG orientation-bias filtering fed into FilterMutectCalls. Use when calling somatic mutations from a tumor-normal pair (or tumor-only with PoN caveats), deciding which artifact filter removes which class of false positive, reasoning about VAF/purity/ploidy and clonal-vs-subclonal detection, adding somatic SV/CNV or TMB/MSI/signatures, or routing variants to AMP/ASCO/CAP tier and oncogenicity interpretation (never germline ACMG).
Chains a somatic (tumor-normal) SNV/indel and structural-variant pipeline end to end with GATK Mutect2 (or Strelka2), wiring the somatic-specific machinery - panel-of-normals and gnomAD germline-resource priors, GetPileupSummaries/CalculateContamination, and LearnReadOrientationModel FFPE/oxoG orientation-bias filtering fed into FilterMutectCalls. Use when calling somatic mutations from a tumor-normal pair (or tumor-only with PoN caveats), deciding which artifact filter removes which class of false positive, reasoning about VAF/purity/ploidy and clonal-vs-subclonal detection, adding somatic SV/CNV or TMB/MSI/signatures, or routing variants to AMP/ASCO/CAP tier and oncogenicity interpretation (never germline ACMG).
Before using code patterns, verify installed versions match. If versions differ:
CLI: <tool> --version then <tool> --help to confirm flags
If code throws ImportError, AttributeError, or TypeError, introspect the installed
package and adapt the example to match the actual API rather than retrying.
Note: this is a WORKFLOW skill - it wires the somatic-specific chain and the DECISIONS between steps. Component mechanism (caller internals, filter thresholds, annotation, CNV) lives in the cross-referenced component skills; interpretation lives in variant-calling/clinical-interpretation and uses the AMP/ASCO/CAP tier system, NOT germline ACMG.
Somatic Variant Pipeline
"Call somatic mutations from my tumor-normal pair" -> Orchestrate somatic SNV/indel calling (Mutect2 or Strelka2) with panel-of-normals + germline-resource priors, contamination and orientation-bias filtering, then somatic SV/CNV, then tier/oncogenicity interpretation.
A somatic callset is not a fact about the tumor; it is a joint property of (tumor, matched normal, caller, filters, reference). Three consequences drive every decision in this pipeline:
There is no universal somatic truth set. The ICGC-TCGA DREAM Mutation Calling challenge (Alioto 2015 Nat Commun 6:10001) gave expert teams the SAME tumor-normal WGS and got widely varying call rates and low SNV concordance - indels and SVs far worse. Somatic reproducibility is intrinsically worse than germline (low VAF, subclonality, purity/ploidy, normal contamination) and there is still no GIAB-grade generalizable somatic reference. Practical corollary: pin the pipeline, benchmark against orthogonal validation for the assay, and prefer multi-caller consensus where feasible - do not treat one caller's VCF as ground truth.
Somatic variants are sub-1.0 VAF and depth/purity-limited. Unlike a germline 0/0.5/1.0 genotype, a somatic variant sits at a continuous allele fraction set by tumor purity, local copy number, and clonal fraction. Detecting a low-VAF subclonal or low-purity variant is a depth problem (the somatic regime is the one place more coverage genuinely helps). This is why Mutect2 uses a somatic likelihood model, not a diploid genotyper.
Somatic interpretation uses a DIFFERENT framework. Never apply germline ACMG (PVS1/PM2/PP3) to a tumor variant - it is a category error. Somatic variants are classified by clinical actionability (AMP/ASCO/CAP tiers, Li 2017) and oncogenicity (ClinGen/CGC/VICC, Horak 2022), and the tier is tumor-type-specific. See the interpretation section and variant-calling/clinical-interpretation.
The four somatic-specific filters - what each removes
The machinery that separates somatic calling from germline is four independent artifact/germline removers. Knowing WHICH false-positive class each addresses is the core decision - do not treat them as interchangeable boilerplate.
Filter
Removes
Built from
When it is critical
Panel of Normals (PoN)
Recurrent technical/site artifacts + common germline that reproduce across normals
40+ unrelated normals from the SAME assay/platform, CreateSomaticPanelOfNormals
Always; the ONLY artifact defense in tumor-only mode
Germline resource (gnomAD AF-only)
Germline variants, via a population-AF prior in the somatic model
af-only-gnomad.vcf.gz (AF field only)
Always; carries the germline burden alone in tumor-only mode
Contamination estimate
Cross-individual sample contamination masquerading as low-VAF somatic
GetPileupSummaries on common biallelic SNPs -> CalculateContamination
Any sample with suspected swap/contamination; low-VAF calls
Orientation-bias model
FFPE deamination (C>T/G>A) and oxoG (C>A/G>T) library artifacts, detected as F1R2/F2R1 strand imbalance
--f1r2-tar-gz from Mutect2 -> LearnReadOrientationModel
FFPE, archival, or oxidatively damaged input; ALWAYS for FFPE
PoN and germline-resource act at CALL time (priors passed to Mutect2); contamination and orientation-bias are learned separately and injected at FILTER time (FilterMutectCalls). The tumor-only trap: without a matched normal, the PoN and germline resource are the ONLY things removing germline and artifacts, so both must be assay-matched and current, and the false-positive rate is materially higher.
Mutect2 tumor-normal workflow
The end-to-end chained script is in examples/run_mutect2.sh; the steps and their decisions:
Step 1: Build a Panel of Normals (do once per assay)
# Each normal called in tumor-only mode; --max-mnp-distance 0 is REQUIRED for GenomicsDBImportfor normal in normal1.bam normal2.bam normal3.bam; do
s=$(basename"$normal" .bam)
gatk Mutect2 -R reference.fa -I "$normal" --max-mnp-distance 0 -O "${s}.vcf.gz"done
gatk GenomicsDBImport -R reference.fa --genomicsdb-workspace-path pon_db \
-V normal1.vcf.gz -V normal2.vcf.gz -V normal3.vcf.gz -L intervals.bed
gatk CreateSomaticPanelOfNormals -R reference.fa -V gendb://pon_db -O pon.vcf.gz
A PoN needs 40+ normals from the same platform/chemistry to capture recurrent artifacts; a PoN from a different assay imports the wrong artifact profile and misses real ones. Do NOT build a PoN from tumor-adjacent normals if they may carry tumor-in-normal contamination.
Step 2: Call somatic variants (tumor + normal in one command)
-normal takes the normal read-group SM name (not the filename). --f1r2-tar-gz collects the read-orientation counts needed in Step 3 - omit it and orientation-bias filtering is impossible. Mutect2 also writes unfiltered.vcf.gz.stats, which FilterMutectCalls reads automatically.
Models the strand-orientation artifacts (oxoG C>A/G>T from oxidative shearing damage; FFPE cytosine-deamination C>T/G>A). These masquerade as low-VAF somatic SNVs; the model lets FilterMutectCalls down-weight them by their F1R2/F2R1 imbalance.
GetPileupSummaries uses a COMMON biallelic-SNP sites resource (e.g. small_exac_common_3.vcf.gz), not the af-only-gnomAD used for the germline prior - it needs sites with a known population AF where reference/alt read counts reveal foreign DNA. --tumor-segmentation also captures allelic-copy segments that feed the filter.
FilterMutectCalls applies a single joint model (contamination + orientation + segmentation + the built-in weak-evidence/germline/strand filters) and sets a per-variant FILTER. Never hand-tune individual thresholds first - the filter is calibrated to balance them together.
Tumor-only mode and its caveats
When no matched normal exists (archival FFPE, cell lines, legacy cohorts):
Decision framing: with no normal, every germline variant is a candidate somatic call, and only the PoN (artifacts) and gnomAD prior (germline) remove them - so both must be assay-matched and the false-positive rate rises sharply. High-VAF (~50% or ~100%) calls are especially suspect for germline. Tumor-only cannot cleanly separate somatic from germline, which creates a disclosure problem (a germline pathogenic finding surfaced as "somatic") - see the interpretation section. Paired tumor-normal is the defensible design; tumor-only requires explicit germline-subtraction logic and reporting caveats.
VAF, purity, ploidy, and clonality
Somatic VAF is not a genotype - it is (clonal_fraction x mutation_copies) / local_total_copies, scaled by tumor purity. Reasoning consequences:
Purity sets sensitivity. At 30% purity a truly clonal heterozygous mutation in diploid regions sits near ~15% VAF; at 10% purity near ~5%. Low-purity samples need higher depth to call the same variant - the one regime where "sequence deeper" is the correct fix (contrast germline, which saturates ~30-35x).
Clonal vs subclonal. High-VAF (adjusted for purity/copy number) variants are clonal (present in most cells, likely early drivers); low-VAF are subclonal (later, spatially/temporally heterogeneous). Clonality informs driver-vs-passenger and treatment-resistance reasoning.
Copy number confounds VAF. A mutation on an amplified allele reads high; on a deleted/LOH background it reads near 1.0. Interpret VAF only alongside local copy number and purity - run copy-number/cnvkit-analysis (or PURPLE) to get purity/ploidy and correct VAF to cancer-cell fraction before calling something subclonal.
Strelka2 is faster and strong on indels (Kim 2018 Nat Methods 15:591); passing Manta's candidateSmallIndels.vcf.gz via --indelCandidates is the documented coupling that improves Strelka2 indel recall.
Multi-caller consensus and reproducibility
Given the Alioto/DREAM discordance, running independent callers and requiring agreement raises precision - the concordant core is the reproducible callset:
Strict all-agree intersection sacrifices too much recall; union admits too many false positives; majority voting (e.g. 2 of 3) balances the two. Normalize every caller's VCF to the same representation first (bcftools norm -f ref.fa -m-) or the intersection undercounts because an indel left-aligned differently in two callers will not match. Consensus is a precision tool, not a substitute for orthogonal validation on the assay.
Somatic SV, CNV, and genomic biomarkers
A complete somatic profile is more than SNVs/indels - hand each off to its component skill:
Structural variants: run Manta in tumor-normal (somatic) mode; it emits somaticSV.vcf.gz. For complex rearrangements/fusions use GRIDSS -> GRIPSS -> LINX. See variant-calling/structural-variant-calling.
Copy number + purity/ploidy: CNVkit (targeted/exome), or PURPLE for allele-specific CN with purity/ploidy fit. Purity/ploidy is a required input for correct VAF-to-cancer-cell-fraction. See copy-number/cnvkit-analysis.
Genomic biomarkers (brief): Tumor Mutational Burden (TMB) = eligible somatic mutations per Mb of covered target (filter out germline and low-VAF artifacts first - inflated TMB is usually residual germline in tumor-only). Microsatellite instability (MSI) is called from indel patterns at microsatellite loci (e.g. MSIsensor). Mutational signatures (SBS/ID/CNV, COSMIC catalogue) attribute the mutation spectrum to processes (APOBEC, UV, MMR-deficiency, platinum) and cross-check artifacts - a dominant C>A/G>T signature can be residual oxoG, not biology. Verify current tool choices and thresholds against the latest docs.
Normalize BEFORE annotating (annotate-then-normalize is an order error): un-normalized records attach annotations to a non-canonical representation and fail to match COSMIC/gnomAD. Full annotation mechanics (transcript choice, MANE, HGVS 3'-shift) live in variant-calling/variant-annotation.
Interpretation: somatic tiers, NOT germline ACMG
This is the critical decision of the whole pipeline and the most common category error. Route the annotated somatic VCF to variant-calling/clinical-interpretation, which applies TWO orthogonal cancer frameworks:
AMP/ASCO/CAP four-tier clinical actionability (Li 2017 J Mol Diagn 19:4-23):
Tier
Meaning
Example
I
Strong clinical significance - FDA-approved therapy or in professional guidelines for THIS tumor type
BRAF V600E in melanoma
II
Potential significance - therapy in a different tumor type, or clinical-trial/multi-study evidence
same variant in a non-approved tumor type
III
Unknown clinical significance (the somatic "VUS")
rare novel missense, no actionability
IV
Benign / likely benign - high population frequency, no oncogenic role
common polymorphism
Tier is tumor-type-specific - the SAME variant can be Tier I in one cancer and Tier II/III in another (no germline-ACMG analog).
Oncogenicity (Horak 2022 Genet Med 24:986): a SEPARATE points-based ClinGen/CGC/VICC axis (Oncogenic / Likely Oncogenic / VUS / Likely Benign / Benign) from hotspot recurrence, functional data, and tumor-type frequency. Oncogenicity (is it a driver) and actionability (is there a drug) are complementary: an oncogenic driver may still be Tier III if no therapy exists.
Driver vs passenger: a tumor carries thousands of somatic mutations; only a few drive it. Hotspot recurrence (COSMIC, Tate 2019), presence in known oncogenes/tumor suppressors, functional evidence, and clonality (clonal drivers vs subclonal passengers) distinguish them.
Knowledgebase evidence levels: OncoKB therapeutic levels 1-4 + R1/R2 (Chakravarty 2017); CIViC evidence items graded A (validated) to E (inferential), read the item not just the letter (Griffith 2017).
Tumor-only germline leak: in tumor-only assays a high-VAF variant may be germline - reporting it as somatic (or applying a somatic tier to a germline pathogenic finding requiring genetic counseling) is a dual danger. Disclose and filter explicitly.
Quality metrics
bcftools query -f '%FILTER\n' filtered.vcf.gz | sort | uniq -c # counts by filter status# Substitution spectrum: excess C>A/G>T flags residual oxoG; excess C>T/G>A flags FFPE deamination
bcftools query -f '%REF>%ALT\n' somatic_final.vcf.gz | sort | uniq -c
# VAF distribution (a spike near 0.5/1.0 in tumor-only suggests residual germline).# -s takes the read-group SM name, NOT the filename -- read it from the BAM header, as Step 2 does.
TUMOR_SM=$(samtools view -H tumor.bam | awk '/^@RG/{for(i=1;i<=NF;i++) if($i ~ /^SM:/){sub(/^SM:/,"",$i); print $i; exit}}')
# -s restricts to the tumor sample: a bare [%AF] iterates BOTH samples and concatenates# them with no separator (0.25 + 0.01 -> "0.250.01"), which awk then silently truncates to 0.25.
bcftools query -s "$TUMOR_SM" -f '[%AF]\n' somatic_final.vcf.gz | awk '{print int($1*100)/100}' | sort -n | uniq -c
Do NOT judge somatic SNVs by a fixed germline-like Ti/Tv (~2-3); the somatic spectrum is signature-dependent, and a collapse toward transversion excess signals artifact contamination, not a target value.
Common Errors
Symptom
Cause
Fix
Flood of germline variants in output
Missing/wrong germline-resource, or tumor-only without a good PoN
Pass --germline-resource af-only-gnomad.vcf.gz; use an assay-matched 40+ normal PoN
Excess C>A/G>T (or C>T/G>A) low-VAF calls
oxoG (or FFPE) artifacts, orientation-bias filter not applied
Emit --f1r2-tar-gz, run LearnReadOrientationModel, pass --ob-priors to FilterMutectCalls
FilterMutectCalls errors on missing stats
unfiltered.vcf.gz.stats not alongside the VCF
Keep the .stats Mutect2 wrote next to the VCF, or pass --stats
GetPileupSummaries gives nonsense contamination
Used af-only-gnomAD instead of a common biallelic-SNP resource
Use small_exac_common_3.vcf.gz (common SNP sites with AF)
Consensus intersection drops real shared calls
VCFs not normalized before bcftools isec
bcftools norm -f ref.fa -m- every caller's VCF first
Low-purity tumor: expected drivers missing
VAF below detection at that purity/depth
Get purity from copy-number; increase depth; correct VAF to cancer-cell fraction
Applied ACMG PVS1/PM2 to a tumor variant
Germline framework used for somatic
Use AMP/ASCO/CAP tiers + oncogenicity via variant-calling/clinical-interpretation
Related Skills
variant-calling/gatk-variant-calling - Mutect2 mechanism and germline HaplotypeCaller context
variant-calling/filtering-best-practices - FilterMutectCalls internals, normalization, hard filters
copy-number/cnvkit-analysis - Somatic CNV, purity/ploidy for VAF-to-cancer-cell-fraction
read-alignment/bwa-alignment - Upstream alignment/dedup/BQSR of tumor and normal BAMs
References
Li MM, Datto M, Duncavage EJ, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of AMP, ASCO, and CAP. Journal of Molecular Diagnostics. 2017;19(1):4-23. doi:10.1016/j.jmoldx.2016.10.002 (four-tier actionability).
Horak P, Griffith M, Danos AM, et al. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): joint recommendations of ClinGen, CGC, and VICC. Genetics in Medicine. 2022;24(5):986-998. doi:10.1016/j.gim.2022.01.001.
Benjamin D, Sato T, Cibulskis K, Getz G, Stewart C, Lichtenstein L. Calling Somatic SNVs and Indels with Mutect2. bioRxiv 861054 (2019). doi:10.1101/861054 (PREPRINT - the Mutect2 somatic workflow reference; never formally journal-published).
Alioto TS, Buchhalter I, Derdak S, et al. A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. Nature Communications. 2015;6:10001. doi:10.1038/ncomms10001 (ICGC-TCGA DREAM; somatic reproducibility).
Kim S, Scheffler K, Halpern AL, et al. Strelka2: fast and accurate calling of germline and somatic variants. Nature Methods. 2018;15(8):591-594. doi:10.1038/s41592-018-0051-x.
Chen X, Schulz-Trieglaff O, Shaw R, et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics. 2016;32(8):1220-1222. doi:10.1093/bioinformatics/btv710.
Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434-443. doi:10.1038/s41586-020-2308-7 (gnomAD; germline-resource / AF prior).
Griffith M, Spies NC, Krysiak K, et al. CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. Nature Genetics. 2017;49:170-174. doi:10.1038/ng.3774 (evidence levels A-E).
Tate JG, Bamford S, Jubb HC, et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Research. 2019;47(D1):D941-D947. doi:10.1093/nar/gky1015 (hotspot recurrence, signatures).
